Newsbenzinga
FDA Greenlights GSK’s First Lung Cancer Drug Ahead of Schedule
· Published
Article summary
GSK wins early FDA approval for Jideytro, a targeted treatment for adults with advanced ROS1-positive non-small cell lung cancer.
An excerpt from the original article.
Comments —
Loading comments…